Biotechnology Analyst Biegler, along with Dr. Rory Shallis, MD from Yale University School of Medicine, preview ASH abstracts (Relevant companies SNDX KURA VOR APTO SYRS) with a focus on key updates expected in the treatment of AML on an Analyst/Industry conference call to be held on November 9 at 10 am.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SNDX:
- Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
- Syndax’s axatilimab shows safety and efficacy in graft-versus-host disease
- Bank of America Says Contrarian Buy Signal Could Push Stocks Higher; Here Are 2 Names the Banking Giant Likes Right Now
- BofA starts ‘misjudged’ Syndax with a Buy
- Syndax initiated with a Buy at BofA
